DISCOVERY & DEVELOPMENT

THERAPEUTICS PLATFORM

We are making important advancements in medicine by harnessing the microbiome as a rich source of novel therapeutics...

THERAPEUTICS PLATFORM

APPROACH

"We aim to transform rigorous scientific insights into groundbreaking microbial products with clinical utility."
GenieBiome leverages one of the first and largest Asian human microbial data-driven approaches to therapeutic discoveries. Our expanding disease-specific microbial datasets in contrast with a comprehensive control dataset delivers a rich source of novel therapeutic candidates. We have exceptional ability to achieve accurate species, functional profiles, and metabolic-pathway analysis.

Our Targeted Microbiome Supplements were derived utilizing large metagenomic microbial datasets and machine-learning approaches to deliver missing microbes and their biologically important functions to correct “dysbiosis” in conditions associated with it.

Our Multi-functional Live Biotherapeutics uses a unique patented approach to isolate novel health-relevant bacteria and disease-specific bacterial isolates/metabolites for pre-clinical experiments with rapid development into effective biotherapeutics for treatment of human diseases.
shutterstock_1122841556.jpg
 

THERAPEUTICS PLATFORM

SOLUTION & PRODUCT

Excellence in Biomedicine
GenieBiome (Therapeutics) launched G-NiiB Immunity product, a microbiome precision formula that improves immunity against Coronavirus (COVID)-19 and other respiratory infections tailored to Asians. 
cuhk-geniebiome-product-img-v01.png
Rejuvenate Your Unique Microbiome
Boosting Your Immunity
G-NiiB Immunity Plus and G-NiiB Immunity Pro are unique microbiome Immunity formulas that can be used as dietary supplements. This formula uses big microbial datasets of over 1000 healthy individuals to select naturally-occurring prevalent live bacteria, in contrast with microbial profile of individuals with COVID-19. It utilizes patented microencapsulated technology from Italy to enhance live bacteria survival and delivery to the colon. Pilot data showed that it is associated with higher antibody response and less adverse effects following COVID-19 vaccine. It is clinically shown to be effective and safe in patients with local novel virus infection.

G-NiiB obtained exclusive patent# licensing from the Chinese University of Hong Kong. 
For more information about G-NiiB Immunity product, please click here